Figure 1.
Figure 1. Influence of neutral evolutionary dynamics on OS and PFS in the Myeloma XI and CoMMpass studies. Kaplan-Meier curves comparing neutral cases (R2 ≥ 0.98) vs nonneutral cases. (A) Progression-free survival (PFS) of Myeloma XI cases in the nonintensive treatment arm. (B) Overall survival (OS) of Myeloma XI cases in the nonintensive treatment arm. (C) PFS of Myeloma XI cases in the intensive treatment arm. (D) OS of Myeloma XI cases in the intensive treatment arm. (E) PFS of nonautologous transplant CoMMpass cases receiving an IMiD. (F) OS of nonautologous transplant CoMMpass cases receiving an IMiD. (G) PFS of autologous transplant CoMMpass cases receiving an IMiD. (H) OS of autologous transplant CoMMpass cases receiving an IMiD. The red line depicts the survival curve for tumors with neutral evolutionary dynamics, and the black line depicts the survival curve for tumors with nonneutral evolutionary dynamics. Horizontal ticks on the survival curves show censored cases.

Influence of neutral evolutionary dynamics on OS and PFS in the Myeloma XI and CoMMpass studies. Kaplan-Meier curves comparing neutral cases (R2 ≥ 0.98) vs nonneutral cases. (A) Progression-free survival (PFS) of Myeloma XI cases in the nonintensive treatment arm. (B) Overall survival (OS) of Myeloma XI cases in the nonintensive treatment arm. (C) PFS of Myeloma XI cases in the intensive treatment arm. (D) OS of Myeloma XI cases in the intensive treatment arm. (E) PFS of nonautologous transplant CoMMpass cases receiving an IMiD. (F) OS of nonautologous transplant CoMMpass cases receiving an IMiD. (G) PFS of autologous transplant CoMMpass cases receiving an IMiD. (H) OS of autologous transplant CoMMpass cases receiving an IMiD. The red line depicts the survival curve for tumors with neutral evolutionary dynamics, and the black line depicts the survival curve for tumors with nonneutral evolutionary dynamics. Horizontal ticks on the survival curves show censored cases.

Close Modal

or Create an Account

Close Modal
Close Modal